Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : NOVARTIS FARMA
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
EVALUATION OF THE QUALITY OF LIFE AND GASTROINTESTINAL SYMPTOMS AFTER CONVERSION TO MYFORTIC (ERL080) and CELLCEPT WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
An extension of a clinical study to investigate long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis Estensione di uno studio clinico per valutare la sicurezza a lungo termine di tobramicina polvere per inalazione (Tobramycin Inhalation Powder – TIP) in pazienti con fibrosi cistica
To assess the safety of Tobramycin Inhalation Powder (TIP) across 12 treatment cycles (6 treatment cycles in the core study and 6 treatment cycles in the extension study) in terms of the incidence...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis
To explore the safety of ICL670 (dose range 5 to 20 mg/kg PO per day) in adult hemochromatosis patients homozygous for the C282Y mutation, with iron overload.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
An extension to a phase II open label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis Estensione dello studio in aperto di fase II per determinare la tollerabilita` e l`efficacia antileucemica di STI571 in pazienti con leucemia mieloide cronica Ph+ in crisi blastica mieloide
To enable patients to have access to study drug and continue study treatment To decrease data collection to include only overall survival and serious adverse events Consentire ai pazienti ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonメs syndrome, non-functioning adenoma, TSH-adenoma, Gonadotroph adenoma, and PRL-adenoma) with potential sensitivity to somatostatin analogues
To evaluate the effect of SOM230 s.c. in patients with rare life threatening diseases as follows: Biochemical tumor markers for those patients with duodeno-pancreatic (neuro) endocrine tumors (insuli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A 24-weeks , national, multicenter, double blind controlled vs placebo trial to evaluate the efficacy of Neoral ciclosporine 5mg/kg/day , twice a week administered in reduction of the rate of relapse in pz with chronic plaque psoriasis on remission. PREWENT Study
Relapse rate during the 24-weeks treatment with Neoral ciclosporine 5mg/kg/day twice a week
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
Project on the promotion of cardiovascular risk evaluation in clinical practice and the assessment of cardiovascular risk evolution after the introduction of a preventive multifactorial strategy aimed at decresing the global risk level (SCORE algorithm), in subjects affected from metabolic syndrome and with a risk level lt; or = 5%
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A single arm, multicenter phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti-EGFR antibody (if appropriate), evacizumab, fluoropyrimidine, oxaliplatin, and irinotecan-based regimens
To assess disease control rate (DCR) and then objective response rate (ORR) as a measure of the anti-tumor activity of RAD001.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
An expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist. Programma di accesso allargato a ranibizumab in pazienti con diminuzione visiva causata dall’edema maculare diabetico per i quali non esistano adeguate alternative terapeutiche
To provide early access to ranibizumab in patients with macular edema and visual impairment secondary to diabetes mellitus for whom no suitable therapeutic alternatives exist (i.e. existing therapies,...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression in patients with quiescent, non-infectious intermediate, posterior or panuveitis (ENDURE Study)
To evaluate the efficacy of three dose regimens of subcutaneous AIN457 compared to placebo for maintaining the suppression of intraocular inflammation and the prevention of an active intermediate, pos...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
Suivant